Table 1.
Patient characteristics.
| No. (%) a of Patients | |||||
|---|---|---|---|---|---|
| Index I | Index II | ||||
| Discovery Cohort (n = 243) |
Replication Cohort (n = 120) |
Discovery Cohort (n = 257) |
Replication Cohort (n = 106) |
Total Population (n = 363) |
|
| Age, median (range) | 68 (42–88) | 68 (38–85) | 68 (38–88) | 68 (40–88) | 68 (38–88) |
| ≥70 years, n (%) | 95 (39.1) | 55 (45.8) | 100 (38.9) | 50 (47.2) | 150 (41.3) |
| Sex, Male | 133 (54.7) | 65 (54.2) | 147 (57.2) | 51 (48.1) | 198 (54.5) |
| Female | 110 (45.3) | 55 (45.8) | 110 (42.8) | 55 (51.9) | 165 (45.5) |
| Stage III | 69 (28.4) | 25 (20.8) | 64 (24.9) | 30 (28.3) | 94 (25.9) |
| IV | 174 (71.6) | 95 (79.2) | 193 (75.1) | 76 (71.7) | 269 (74.1) |
| ECOG Performance Status 0 | 106 (43.6) | 53 (44.2) | 108 (42.0) | 51 (48.1) | 159 (43.8) |
| 1 | 121 (49.8) | 59 (49.2) | 128 (49.8) | 52 (49.1) | 180 (49.6) |
| 2 | 12 (4.9) | 7 (5.8) | 16 (6.2) | 3 (2.8) | 19 (5.2) |
| Unknown | 4 (1.7) | 1 (0.8) | 5 (1.9) | 0 (0.0) | 5 (1.4) |
| Diabetes | 65 (26.7) | 24 (20.0) | 60 (23.3) | 29 (27.4) | 89 (24.5) |
| Smoking, Former | 91 (37.5) | 56 (46.7) | 106 (41.2) | 41 (38.7) | 147 (40.5) |
| Current | 60 (24.7) | 27 (22.5) | 66 (25.7) | 21 (19.8) | 87 (24.0) |
| Never | 80 (32.9) | 34 (28.3) | 72 (28.0) | 42 (39.6) | 114 (31.4) |
| Unknown | 12 (4.9) | 3 (2.5) | 13 (5.1) | 2 (1.9) | 15 (4.1) |
| Time from diagnosis to baseline sample, days b | 21 (16–29) | 20 (15–33) | 21 (16–31) | 20 (16–27) | 21 (16–31) |
| Overall survival, months b | 8 (5–15) | 10 (5–17) | 8 (5–15) | 7 (4–16) | 8 (4–15) |
| Baseline CA19-9, kU/L b | 1070 (165–7285) |
886 (92–5863) |
840 (128–6675) |
2180 (175–6770) |
998 (132–6770) |
| Gemcitabine | 126 (51.9) | 57 (47.5) | 127 (49.4) | 56 (52.8) | 183 (50.4) |
| Gemcitabine + nab-paclitaxel | 50 (20.6) | 32 (26.7) | 56 (21.8) | 26 (24.5) | 82 (22.6) |
| mFOLFIRINOX | 67 (27.5) | 31 (25.8) | 74 (28.8) | 24 (22.6) | 98 (27.0) |
a Unless otherwise noted; b median (interquartile range). Abbreviations: ECOG—Eastern Cooperative Oncology Group.